liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: Novel treatment predictive factors identified
Linköping University, Department of Medical and Health Sciences, Clinical Pharmacology. Linköping University, Faculty of Health Sciences.
Linköping University, Department of Clinical and Experimental Medicine, Oncology. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Centre for Surgery, Orthopaedics and Cancer Treatment, Department of Oncology UHL.
Central Hospital, Karlstad.
Karolinska University Hospital, Stockholm.
Show others and affiliations
2011 (English)In: Cancer Letters, ISSN 0304-3835, E-ISSN 1872-7980, Vol. 313, no 2, 145-153 p.Article in journal (Refereed) Published
Abstract [en]

We investigated the efficacy and safety of single-agent pegylated liposomal doxorubicin (PLD) as first-line treatment for elderly women with advanced breast cancer and evaluated predictive markers for response and toxicity. Twenty-five women ⩾65years received 40mg/m(2) PLD every 28days. Time to treatment failure (TTF), response rate, time to progression (TTP) and overall survival (OS) was calculated. The ABCB1 single nucleotide polymorphisms (SNP), tumor MRN complex, and TOPOIIα were analyzed. A mean of 7.4 cycles PLD were administered and TTF was 5.5months and OS 20.6months. ABCB1 SNPs were found to correlate to both efficacy and toxicity, while tumor expression of the MRN complex and TOPOIIα correlated to TTP. PLD is a safe and effective treatment for elderly breast cancer patients. Also potential predictive markers were identified.

Place, publisher, year, edition, pages
Elsevier, 2011. Vol. 313, no 2, 145-153 p.
Keyword [en]
Anthracycline, Elderly, Genotype, Metastatic breast cancer, MRN complex, Topoisomerase IIa
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-73049DOI: 10.1016/j.canlet.2011.07.017ISI: 000297895800004PubMedID: 22056077OAI: oai:DiVA.org:liu-73049DiVA: diva2:467896
Available from: 2011-12-20 Created: 2011-12-14 Last updated: 2017-12-08

Open Access in DiVA

fulltext(582 kB)339 downloads
File information
File name FULLTEXT01.pdfFile size 582 kBChecksum SHA-512
5e819ee97ff110e18c4cae4a1b720d899ddc137dfc07608692968b8d9e76ef4ef7858e0a61180f88798d51b3e3104ce9685f572f8dd049730f709f6eecdafccf
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Green, HenrikStål, OlleMalmström, Annika

Search in DiVA

By author/editor
Green, HenrikStål, OlleMalmström, Annika
By organisation
Clinical PharmacologyFaculty of Health SciencesOncologyDepartment of Oncology UHLCell BiologyLAH Linköping
In the same journal
Cancer Letters
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 339 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 165 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf